{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:42:16Z","timestamp":1790196136515,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jaut.2017.07.006","type":"journal-article","created":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T10:15:41Z","timestamp":1499854541000},"page":"65-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Anti-IL-21 monoclonal antibody combined with liraglutide effectively reverses established hyperglycemia in mouse models of type 1 diabetes"],"prefix":"10.1016","volume":"84","author":[{"given":"Anna K.","family":"Ryd\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikole R.","family":"Perdue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9026-4549","authenticated-orcid":false,"given":"Philippe P.","family":"Pagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire B.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sowbarnika S.","family":"Ratliff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke K.","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9445-3785","authenticated-orcid":false,"given":"Travis J.","family":"Friesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Haase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Coppieters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias G.","family":"von Herrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar E.","family":"Boursalian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2017.07.006_bib1","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2337\/diabetes.54.6.1763","article-title":"A\u00a0single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes","volume":"54","author":"Herold","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.jaut.2017.07.006_bib2","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00125-009-1644-9","article-title":"Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass","volume":"53","author":"Keymeulen","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.jaut.2017.07.006_bib3","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0140-6736(11)60886-6","article-title":"Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial","volume":"378","author":"Orban","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2017.07.006_bib4","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jaut.2017.07.006_bib5","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/blood-2009-02-204875","article-title":"Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients","volume":"115","author":"Keymeulen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2017.07.006_bib6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jcv.2013.01.016","article-title":"Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes","volume":"57","author":"Kroll","year":"2013","journal-title":"J.\u00a0Clin. Virol."},{"key":"10.1016\/j.jaut.2017.07.006_bib7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clim.2013.02.003","article-title":"Anti-cytokine therapies in T1D: concepts and strategies","volume":"149","author":"Nepom","year":"2013","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jaut.2017.07.006_bib8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.imbio.2015.09.021","article-title":"Biological effects of IL-21 on different immune cells and its role in autoimmune diseases","volume":"221","author":"Gharibi","year":"2016","journal-title":"Immunobiology"},{"key":"10.1016\/j.jaut.2017.07.006_bib9","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrd4296","article-title":"Interleukin-21: a double-edged sword with therapeutic potential","volume":"13","author":"Spolski","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jaut.2017.07.006_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/35040504","article-title":"Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function","volume":"408","author":"Parrish-Novak","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2017.07.006_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev.immunol.26.021607.090316","article-title":"Interleukin-21: basic biology and implications for cancer and autoimmunity","volume":"26","author":"Spolski","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jaut.2017.07.006_bib12","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.humimm.2007.01.009","article-title":"Molecular scanning of interleukin-21 gene and genetic susceptibility to type 1 diabetes","volume":"68","author":"Asano","year":"2007","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.jaut.2017.07.006_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8848","article-title":"A\u00a0divergent population of autoantigen-responsive CD4+ T cells in infants prior to beta cell autoimmunity","volume":"9","author":"Heninger","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jaut.2017.07.006_bib14","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00125-015-3509-8","article-title":"IL-21 production by CD4+ effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients","volume":"58","author":"Ferreira","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.jaut.2017.07.006_bib15","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1172\/JCI76238","article-title":"Follicular helper T cell signature in type 1 diabetes","volume":"125","author":"Kenefeck","year":"2015","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.jaut.2017.07.006_bib16","doi-asserted-by":"crossref","first-page":"14028","DOI":"10.1073\/pnas.0804358105","article-title":"IL-21 signaling is critical for the development of type I diabetes in the NOD mouse","volume":"105","author":"Spolski","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jaut.2017.07.006_bib17","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.2337\/db08-0882","article-title":"Interleukin-21 is required for the development of type 1 diabetes in NOD mice","volume":"58","author":"Sutherland","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.jaut.2017.07.006_bib18","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.immuni.2012.04.005","article-title":"Interleukin-21 receptor-mediated signals control autoreactive T cell infiltration in pancreatic islets","volume":"36","author":"Van Belle","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2017.07.006_bib19","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2337\/db10-1157","article-title":"Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models","volume":"60","author":"McGuire","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.jaut.2017.07.006_bib20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2337\/db14-1514","article-title":"Deciphering metabolic messages from the gut drives therapeutic innovation: the 2014 Banting Lecture","volume":"64","author":"Drucker","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.jaut.2017.07.006_bib21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.drudis.2011.08.017","article-title":"The potential of incretin-based therapies in type 1 diabetes","volume":"17","author":"Suen","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jaut.2017.07.006_bib22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.clim.2013.04.006","article-title":"GLP-1 agonists in type 1 diabetes","volume":"149","author":"Pettus","year":"2013","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jaut.2017.07.006_bib23","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1210\/en.2007-0358","article-title":"Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells","volume":"148","author":"Sherry","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.jaut.2017.07.006_bib24","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.2337\/diabetes.53.7.1700","article-title":"Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4","volume":"53","author":"Ogawa","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.jaut.2017.07.006_bib25","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.bbrc.2006.03.177","article-title":"Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes","volume":"344","author":"Yang","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jaut.2017.07.006_bib26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/eji.1830060713","article-title":"Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion","volume":"6","author":"Kohler","year":"1976","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jaut.2017.07.006_bib27","doi-asserted-by":"crossref","first-page":"e0126003","DOI":"10.1371\/journal.pone.0126003","article-title":"Liraglutide improves pancreatic Beta cell mass and function in alloxan-induced diabetic mice","volume":"10","author":"Tamura","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.jaut.2017.07.006_bib28","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2337\/diacare.26.3.832","article-title":"Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial","volume":"26","author":"Steffes","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaut.2017.07.006_bib29","doi-asserted-by":"crossref","first-page":"838","DOI":"10.4161\/hv.26890","article-title":"Non-antigenic and antigenic interventions in type 1 diabetes","volume":"10","author":"Ryden","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jaut.2017.07.006_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2217\/imt.10.23","article-title":"Combination therapies for type 1 diabetes: why not now?","volume":"2","author":"von Herrath","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jaut.2017.07.006_bib31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.immuni.2005.08.002","article-title":"A\u00a0comprehensive review of interventions in the NOD mouse and implications for translation","volume":"23","author":"Shoda","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2017.07.006_bib32","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/nri1502","article-title":"Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes","volume":"4","author":"Roep","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2017.07.006_bib33","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1172\/JCI27191","article-title":"Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs","volume":"116","author":"Bresson","year":"2006","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.jaut.2017.07.006_bib34","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4049\/jimmunol.168.2.933","article-title":"Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance","volume":"168","author":"von Herrath","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jaut.2017.07.006_bib35","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/db13-1257","article-title":"Combination therapy with an anti-IL-1beta antibody and GAD65 DNA vaccine can reverse recent-onset diabetes in the RIP-GP mouse model","volume":"63","author":"Pagni","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.jaut.2017.07.006_bib36","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.4049\/jimmunol.1201730","article-title":"IL-21 promotes CD8+ CTL activity via the transcription factor T-bet","volume":"190","author":"Sutherland","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jaut.2017.07.006_bib37","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.4049\/jimmunol.180.8.5393","article-title":"Release from regulatory T cell-mediated suppression during the onset of tissue-specific autoimmunity is associated with elevated IL-21","volume":"180","author":"Clough","year":"2008","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jaut.2017.07.006_bib38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1152\/physrev.00003.2010","article-title":"Type 1 diabetes: etiology, immunology, and therapeutic strategies","volume":"91","author":"van Belle","year":"2011","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.jaut.2017.07.006_bib39","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1172\/JCI81722","article-title":"Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients","volume":"125","author":"Rigby","year":"2015","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.jaut.2017.07.006_bib40","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5414\/CP202474","article-title":"Safety, PK, and PD of recombinant anti-interleukin-21 monoclonal antibody in a first-in-human trial","volume":"54","author":"Ignatenko","year":"2016","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jaut.2017.07.006_bib41","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.2337\/db09-0685","article-title":"Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB","volume":"58","author":"Cunha","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.jaut.2017.07.006_bib42","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2337\/db07-1214","article-title":"Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway","volume":"57","author":"Ferdaoussi","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.jaut.2017.07.006_bib43","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1677\/JOE-06-0148","article-title":"Protection of pancreatic beta-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in\u00a0vivo and in\u00a0vitro studies","volume":"193","author":"Tsunekawa","year":"2007","journal-title":"J.\u00a0Endocrinol."},{"key":"10.1016\/j.jaut.2017.07.006_bib44","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cmet.2006.10.001","article-title":"GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress","volume":"4","author":"Yusta","year":"2006","journal-title":"Cell Metab."},{"key":"10.1016\/j.jaut.2017.07.006_bib45","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s00125-011-2069-9","article-title":"The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes","volume":"54","author":"Shimoda","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.jaut.2017.07.006_bib46","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.bbrc.2013.10.026","article-title":"Effect of Liraglutide on endoplasmic reticulum stress in diabetes","volume":"441","author":"Zhao","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jaut.2017.07.006_bib47","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2337\/dc16-0690","article-title":"Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the adjunct two randomized trial","volume":"39","author":"Ahren","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaut.2017.07.006_bib48","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.2337\/dc16-0691","article-title":"Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the adjunct one treat-to-target randomized trial","volume":"39","author":"Mathieu","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaut.2017.07.006_bib49","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1172\/JCI200316409","article-title":"Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood","volume":"111","author":"Trudeau","year":"2003","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.jaut.2017.07.006_bib50","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/nm.3705","article-title":"Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress","volume":"20","author":"Hasnain","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.jaut.2017.07.006_bib51","doi-asserted-by":"crossref","first-page":"e0146818","DOI":"10.1371\/journal.pone.0146818","article-title":"Interleukin-22 alleviated palmitate-induced endoplasmic reticulum stress in INS-1 cells through activation of autophagy","volume":"11","author":"Hu","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.jaut.2017.07.006_bib52","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature13564","article-title":"Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes","volume":"514","author":"Wang","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2017.07.006_bib53","first-page":"2","article-title":"The involvement of interleukin-22 in the expression of pancreatic beta cell regenerative Reg genes","volume":"2","author":"Hill","year":"2013","journal-title":"Cell Regen. (Lond)"},{"key":"10.1016\/j.jaut.2017.07.006_bib54","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1006\/jaut.2002.0604","article-title":"Gamma interferon paradoxically inhibits the development of diabetes in the NOD mouse","volume":"19","author":"Sobel","year":"2002","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.jaut.2017.07.006_bib55","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1084\/jem.180.3.995","article-title":"Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process","volume":"180","author":"Yang","year":"1994","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.jaut.2017.07.006_bib56","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.4049\/jimmunol.179.6.3638","article-title":"Granulocyte-macrophage colony-stimulating factor prevents diabetes development in NOD mice by inducing tolerogenic dendritic cells that sustain the suppressive function of CD4+CD25+ regulatory T cells","volume":"179","author":"Gaudreau","year":"2007","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jaut.2017.07.006_bib57","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jdiacomp.2008.12.004","article-title":"Exendin-4 treatment of nonobese diabetic mice increases beta-cell proliferation and fractional insulin reactive area","volume":"24","author":"Xue","year":"2010","journal-title":"J.\u00a0Diabetes Complicat."},{"key":"10.1016\/j.jaut.2017.07.006_bib58","doi-asserted-by":"crossref","first-page":"e35801","DOI":"10.1371\/journal.pone.0035801","article-title":"In\u00a0vitro proliferation of adult human beta-cells","volume":"7","author":"Rutti","year":"2012","journal-title":"PloS One"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841117302597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841117302597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:16:22Z","timestamp":1760256982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841117302597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":58,"alternative-id":["S0896841117302597"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2017.07.006","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-IL-21 monoclonal antibody combined with liraglutide effectively reverses established hyperglycemia in mouse models of type 1 diabetes","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2017.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}